Alcon receives FDA approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
AcrySof IQ Aspheric Intraocular Lens (IOL) with UltraSert pre-loaded delivery system helps maintain integrity of incision while facilitating smooth IOL delivery.
Alcon has received FDA approval for its AcrySof IQ Aspheric IOL with the UltraSert pre-loaded delivery system for patients undergoing cataract surgery. This new delivery system combines the control of a manually loaded device with the safety and convenience of a disposable, pre-loaded injector to optimize the implantation of the AcrySof IQ Aspheric IOL into the cataract patient's eye. Nearly four million cataract surgeries are performed each year in the US. The UltraSert pre-loaded delivery system received the European CE mark in June 2015.
"The introduction of the UltraSert pre-loaded delivery system further reinforces our commitment to advancing cataract surgery through innovation," said Sergio Duplan, Region President, US and Canada. "We are addressing a distinct need of cataract surgeons for a single-use system that maximizes their control during surgery and helps them streamline procedures to enable improved patient outcomes."
In cataract surgery, controlling the speed of delivery of the IOL when inserted into the eye is an important factor in achieving a successful cataract procedure. Alcon has addressed this critical factor in the UltraSert pre-loaded delivery system with the TensionGlide plunger, a spring-controlled mechanism designed for a smooth, controlled delivery of the AcrySof IQ IOL into the capsular bag. In addition, the UltraSert pre-loaded delivery system features a plunger tip which is designed to support consistent IOL folding and precise placement into the capsular bag of the eye.
The design of the new UltraSert pre-loaded delivery system also helps to create a less invasive corneal incision during cataract surgery. The smaller nozzle tip allows for a corneal incision down to 2.2 mm for insertion of the IOL while the Depth Guard nozzle of the delivery system prevents the device from being inserted deeper into the incision than necessary, preserving the size of the original corneal incision.
"In testing this device, I was immediately impressed with its smooth control and single hand delivery," said Dr Robert Lehmann, a practicing ophthalmologist at the Lehmann Eye Center of Nacogdoches, Texas, USA. "I believe it will give the surgeon excellent control during the procedure to ensure a consistent delivery of the IOL into the eye. There are many surgeons who are highly interested in pre-loaded devices, and UltraSert represents a major step forward in pre-loaded delivery system technology."
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance